Targeted drug shrinks tumors in 3 out of 4 patients with advanced breast cancer

A phase 3 clinical trial published in JAMA found trastuzumab rezetecan was linked to a 73% lower risk of cancer progression or death compared to chemotherapy in patients with advanced breast cancer. The trial tested the drug in patients with HER2-positive tumors. Results showed tumor shrinkage in approximately 3 out of 4 patients receiving the drug.

• Fox News — Targeted drug shrinks tumors in 3 out of 4 patients with advanced breast cancer

Next story